How have EMIS shares performed in 2024?

Emisphere Technologies' stock was trading at $7.81 at the start of the year. Since then, EMIS stock has increased by 0.0% and is now trading at $7.81. View the best growth stocks for 2024 here .

How were Emisphere Technologies' earnings last quarter?

Emisphere Technologies, Inc. (OTCMKTS:EMIS) posted its earnings results on Friday, May, 12th. The company reported $0.04 earnings per share (EPS) for the quarter. The firm had revenue of $0.22 million for the quarter.

What other stocks do shareholders of Emisphere Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emisphere Technologies investors own include Novo Nordisk A/S (NVO) , Fulcrum Therapeutics (FULC) , VIVUS (VVUS) , Allena Pharmaceuticals (ALNA) , Capricor Therapeutics (CAPR) , Aldeyra Therapeutics (ALDX) , CymaBay Therapeutics (CBAY) , Cerecor (CERC) and Cumberland Pharmaceuticals (CPIX) .

How do I buy shares of Emisphere Technologies?

Shares of EMIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:EMIS

Emisphere Technologies (EMIS) Stock Price, News & Analysis

→ This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad)

Free EMIS Stock Alerts

$7.81

0.00 (0.00%)

(As of 12/9/2020)

Compare

Today's Range: $7.81
▼
$7.81
50-Day Range: $7.81
▼
$7.81
52-Week Range: $4.06
▼
$9.16

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Emisphere Technologies alerts:

Ad DTI

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

About Emisphere Technologies Stock (OTCMKTS:EMIS)

Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.

EMIS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EMIS Stock News Headlines

March 3, 2024 | ca.finance.yahoo.com

Exco Technologies Limited (XTC.TO)

December 11, 2023 | dailymail.co.uk

Insulin pill could free diabetics from jabs

April 16, 2024 | DTI (Ad)

A new way to collect income from stocks

November 19, 2023 | barrons.com

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Emisphere Technologies, Inc. with Losses of $100,000 to Contact the Firm

October 23, 2023 | businesswire.com

EMIS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Emisphere Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

October 5, 2023 | benzinga.com

Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Emisphere Technologies, Inc.

May 8, 2023 | finance.yahoo.com

Buccal Drug Delivery System Global Market Report 2023

May 4, 2023 | msn.com

Flying high on obesity success, Novo's appetite for deals grows

April 16, 2024 | DTI (Ad)

A new way to collect income from stocks

April 16, 2023 | marketwatch.com

Informative Market Research Report on Thrombin Inhibitor with Estimated CAGR of 12.5% from 2023-2030

April 11, 2023 | uk.finance.yahoo.com

Oral Biologics & Biosimilars Global Market Report 2023

March 2, 2023 | marketwatch.com

Incretin-Based Drugs Market Size Regional Analysis 2023 which includes Rapid Growth Rate Till 2025

February 19, 2023 | marketwatch.com

Global Non-insulin Diabetes Therapeutics Market Size Analysis, Share, Application, Opportunities Forecast to 2030 By VMReports

February 14, 2023 | marketwatch.com

Insulin Detemir Market 2023 Size, Share, Applications, Advance Technology And Top Companies To 2026

September 23, 2022 | benzinga.com

Oral Biologics & Biosimilars Global Market Report 2022

July 20, 2022 | benzinga.com

Diabetes Devices Market Size is projected to reach USD 49.25 Billion by 2030, growing at a CAGR of 6.62%: Straits Research

March 10, 2022 | marketwatch.com

Oral Drug Delivery Market Analysis, Key Players, Segmentation, Application And rate of 7.60% in the forecast period of 2022 to 2029

February 24, 2022 | za.investing.com

Emisphere Tech (EMIS)

February 22, 2022 | fool.com

Emisphere Technologies, Inc.(EMIS)

January 17, 2022 | thestreet.com

Health Stocks in Motion

December 19, 2021 | law360.com

Law360 Pulse's Spotlight On Mid-Law Work

November 18, 2021 | bloomberg.com

Former NFL Quarterback, MLB Pitcher Chad Hutchinson is Now a Sports PE Executive

November 18, 2021 | law360.com

3 Firms Lead Novo Nordisk's $3.3B Dicerna Buy

November 4, 2021 | marketwatch.com

Novo Nordisk's New Obesity Drug Boosted 3Q Earnings -- Earnings Review

October 15, 2021 | law360.com

Counsel In $1.8B Biotech Sale Suit Urged To Work Together

September 23, 2021 | marketwatch.com

Thrombin Inhibitors Market Trends, Size, Market Share, Growth Factor, Opportunities, Segment, Top Manufacturers, Drivers and Forecast 2021-2026

September 7, 2021 | law360.com

Lead Counsel Battle Heats Up In $1.8B Biotech Sale Suit

See More Headlines

Receive EMIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emisphere Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/12/2017
Today: 4/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:EMIS
CUSIP: N/A
CIK: 805326
Web: www.emisphere.com
Phone: 973-532-8000
Fax: 973-422-0125
Employees: 6
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Alan L. Rubino (Age 65)
Advisor
Mr. Alan V. Gallantar CPA (Age 62)
Interim Chief Financial Officer

Key Competitors

View All Competitors

EMIS Stock Analysis - Frequently Asked Questions

How have EMIS shares performed in 2024?: Emisphere Technologies' stock was trading at $7.81 at the start of the year. Since then, EMIS stock has increased by 0.0% and is now trading at $7.81.
View the best growth stocks for 2024 here.
How were Emisphere Technologies' earnings last quarter?: Emisphere Technologies, Inc. (OTCMKTS:EMIS) posted its earnings results on Friday, May, 12th. The company reported $0.04 earnings per share (EPS) for the quarter. The firm had revenue of $0.22 million for the quarter.
What other stocks do shareholders of Emisphere Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Emisphere Technologies investors own include Novo Nordisk A/S (NVO), Fulcrum Therapeutics (FULC), VIVUS (VVUS), Allena Pharmaceuticals (ALNA), Capricor Therapeutics (CAPR), Aldeyra Therapeutics (ALDX), CymaBay Therapeutics (CBAY), Cerecor (CERC) and Cumberland Pharmaceuticals (CPIX).
How do I buy shares of Emisphere Technologies?: Shares of EMIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:EMIS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Emisphere Technologies (EMIS) Stock Price, News & Analysis

About Emisphere Technologies Stock (OTCMKTS:EMIS)

EMIS Stock Price History

EMIS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

EMIS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info